A Journey Through Guidelines, Consensus, Curriculum of Educators and Clinical Practice on Insulin-Induced Skin Lipohypertrophy: From the Earth to the Moon

Main Article Content

Sandro Gentile Ersilia Satta Giuseppina Guarino Carmine Romano Adalgisa Maffettone Erika Eliana Heinke Elvira Donnarumma Romina Castellano Salvatore Izzo Iolanda Manzo Felice Strollo

Abstract

This minireview wants to draw the readers' attention to a neglected complication of insulin therapy, i.e., lipohypertrophy due to injection errors. The considerable diffusion of lipohypertrophy represents evidence of a lack of education and monitoring. This phenomenon occurs despite international recommendations on correct injection techniques in the latest American Diabetes Association Standards of Medical Care in Diabetes edition. There are no precise indications in the literature for well-organized courses for educators like those promoted by the International Diabetes Federation. The damage caused by LH, such as poor glycemic control, significant blood sugar variability, and unexpected hypoglycemic events, represents a high risk for acute and chronic complications of diabetes and an increase in health and social costs. Unfortunately, as reported by the WHO, health costs tend to increase spontaneously over time and have been increasing recently with the COVID-19 pandemic, which has also enormously contributed to new cases of diabetes. For all this, a call to action is required for errors in insulin injection techniques across the board, involving university programs, specialization programs, joint efforts of all scientific endocrinology-related societies, manufacturers of insulin and injection devices, and Ministries of health.

Keywords: diabetes, insulin, injection technique, lipohypertrophy, education

Article Details

How to Cite
GENTILE, Sandro et al. A Journey Through Guidelines, Consensus, Curriculum of Educators and Clinical Practice on Insulin-Induced Skin Lipohypertrophy: From the Earth to the Moon. Medical Research Archives, [S.l.], v. 10, n. 9, sep. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/3019>. Date accessed: 24 nov. 2024. doi: https://doi.org/10.18103/mra.v10i9.3019.
Section
Research Articles

References

1. HISTORY OF DIABETES - The treatment with insulin.
http://www.museodeldiabete. com/storia14.htm#top, last consultation 28 May 2022
2. Injection-Related Local Side Effects in the Treatment of Diabetes Mellitus: A Methodological Approach and Possible Solutions. Consensus Statement of Amd-Osdi Study Group on Injection Technique. Gentile S, Strollo F, Rosa N, Grassi G, Lalli C, Lo Grasso G. et al. In e-book Diabetes Complications 2016. www.smgebooks.com/diabetic-complications/index.php
3. Gentile S, Grassi G, Armentano V, et al. AMD-OSDI Consensus on Injection Techniques for People with Diabetes Mellitus. Med Clin Rev. 2016, 2:3. DOI: 10.21767/2471-299X.1000034
4. Milan G, Murano I, Costa S, Pianta A, Tiengo C, Zulato E, Centobene C, Bruttomesso D, Cinti S, Vettor R. Lipoatrophy induced by subcutaneous insulin infusion: ultrastructural analysis and gene expression profiling. J Clin Endocrinol Metab. 2010 Jul;95(7):3126-32. doi: 10.1210/jc.2009-2773. Epub 2010 May 19. PMID: 20484470.
5. Gentile S, Agrusta M, Guarino G, et al. Metabolic consequence of incorrect insulin administration techniques in aging subjects with diabetes. Acta Diabetol. 2011;48:121–125. doi: 10.1007/s00592-009-0172-x.
6. Gentile S, Strollo F, Della Corte T, Marino G, Guarino G. Insulin related lipodystrophic lesions and hypoglycemia: Double standards? Diabetes Metab Syndr. 2018 Sep;12(5):813-818. doi: 10.1016/j.dsx.2018.04.023. Epub 2018 Apr 10. PMID: 29703450.
7. Gentile S, Guarino G, Corte TD, et al. Insulin-induced skin lipohypertrophy in type 2 diabetes: a multicenter regional survey in Southern Italy. Diabetes Ther. 2020;11(9):2001–17. https://doi.org/10.1007/s13300-020-00876-0 (Epub 2020 Jul 18. PMID: 32683659; PMCID: PMC7435140).
8. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab 2013;39:445- 453
9. Gentile S, Guarino G, Giancaterini A, Guida P, Strollo F, AMD-OSDI Italian Injection Technique Study Group. A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes. Springerplus. (2016) 5:563. doi: 10.1186/s40064-016-1978-y
10. Gentile S, Strollo F, Guarino G, et al. Factors hindering correct identification of unapparent lipohypertrophy. J Diabetes Metab Disord Control. 2016; 3(2): 42-47. DOI: 10.15406/ jdmdc. 2016.03.00065
11. Gentile S, Strollo F, Guarino G, et al. Why are so huge differences reported in the occurrence rate of skin lipohypertrophy? Does it depend on method defects or on lack of interest? Diabetes Metab Syndr. 2019;13(1):682–6. https://doi.org/10.1016/j.dsx.2018.11.042
12. Gentile S, Strollo F, Della Corte T, Marino G, Guarino G. Insulin related lipodystrophic lesions and hypoglycemia: Double standards? Diabetes Metab Syndr. 2018 Sep;12(5):813-818. doi: 10.1016/j.dsx.2018.04.023. Epub 2018 Apr 10. PMID: 29703450
13. Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients: a systematic review and meta-analysis. J Diabetes Investig. 2017;9:536–43.
14. Relazione al Parlamento 2021 sul diabete mellito. Istat 2021, Ministero della salute. https://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=5900
15. Rapporto ARNO Diabete 2019. https://www.siditalia.it/news/2547-21-11-2019-rapporto-arno-diabete-2019.
16. Ji L, Sun Z, Li Q, et al. Lipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact. Diabetes Technol Ther. 2017;19(1): 61–7. https://doi.org/10.1089/dia.2016.0334
17. Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients. A systematic review and meta-analysis. J Diabetes Investig 2017;9:536e43.
18. Gentile S, Guarino G, Della Corte T, et al. Role of structured education in reducing lypodistrophy and its metabolic complications in insulin-treated people with type 2 diabetes: a randomized multicenter case-control study. Diabetes Ther. 2021;12(5): 1379–98. https://doi.org/10.1007/s13300-021- 01006-0 (Epub 2021 Mar 18).
19. Gentile S, Guarino G, Della Corte T, et al. The durability of an intensive, structured educationbased rehabilitation protocol for best insulin injection practice: the ISTERP-2 study. Diabetes Ther. 2021;12(9):2557–69. https://doi.org/10.1007/ s13300-021-01108-9 (Epub 2021 Aug 12)
20. Gentile S, Guarino G, Della Corte T, et al. The Economic Burden of Insulin Injection-Induced Lipohypertophy. Role of Education: The ISTERP-3 Study. Adv Ther. 2022 May;39(5):2192-2207. doi: 10.1007/s12325-022-02105-5. Epub 2022 Mar 19. Erratum in: Adv Ther. 2022 Apr 28;: PMID: 35306633; PMCID: PMC9056437.
21. Gentile S, Satta E, Guarino G, at al. Why do so many people with type 2 diabetes who take insulin have lipohypertrophy? fate or educational deficiencies? Diab Therap 2021, in press
22. McLaughlin S, Chaney D, Belton A, Garst J. INTERNATIONAL STANDARDS FOR EDUCATION OF DIABETES HEALTH PROFESSIONALS. International Diabetes Federation, 2015. https://www.idf.org/file:///C:/Users/Luca/Downloads/Standards-of-Professional-Education-in-Diabetes-Final.pdf.
23. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022 Diabetes Care 2022;45(Suppl. 1):S125–S143 | https://doi.org/10.2337/dc22-S009
24. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc 2016;91:1231–1255
25. Bergenstal RM, Strock ES, Peremislov D, Gibney MA, Parvu V, Hirsch LJ. Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes. Mayo Clin Proc 2015;90:329–338
26. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes 2022. Diabetes Care 2022; 45 (Suppl. 1): S46–S59 https://doi.org/10.2337/dc22-S004
27. Sun H, Saeedi P, Karuranga S, et al.. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6. PMID: 34879977.
28. IDF Diabetes Atlas 2021 – 10th edition | www.diabetesatlas.org | https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf4
29. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 – 11 March 2020. WHO: May 11 2020. Available from: https://www.who.int/ director-general/speeches/detail/who-director-generals-opening-remarks-at-the-media-briefing-on-covid-19-11- march-2020
30. Wu C, Chen X, Cai Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13; 180(7):934-943; DOI:10.1001/ jamainternmed.2020.0994
31. Hu Y, Sun J., Dai Z, Deng H, Li X, Huang Q. Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis. J Clin Virol. 2020 Jun; 127:104371. DOI: 10.1016/j.jcv.2020.104371
32. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and metaregression. Diabetes Metab Syndr. 2020 Jul-Aug; 14(4):395- 403. Epub 2020 April 17. DOI: 10.1016/j.dsx.2020.04.018
33. Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. Diabetes Res Clin Pract. 2020 May 22; (165); DOI: 10.1016/j.diabres.2020.108227
34. Killerby ME, Link-Gelles, R, Haight SC, Schrodt CA, England L, Gomes DJ et al. Characteristics Associated with Hospitalization Among Patients with COVID-19 — Metropolitan Atlanta, Georgia, March–April 2020. MMWR Morb Mortal Wkly Rep. 2020 June 26; 69(25);790–794; DOI: http://dx.doi. org/10.15585/mmwr.mm6925e1
35. Thompson DC, Barbu MG, Beiu C, Popa LG, Mihai MM, Berteanu, M et al. The Impact of COVID-19 Pandemic on LongTerm Care Facilities Worldwide: An Overview on International Issues. Biomed Res Int. 2020 Nov 4; 8870249. DOI: 10.1155/2020/8870249
36. Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia. 2021 April 28; 64(7): 1480–1491. DOI: 10.1007/s00125-021-05458-8
37. Do JY, Kim SW, Park JW, Cho KH, Kang, SH. Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Diabetes Metab. 2021 Jul; 47(4):101208. Epub 2020 Nov 4. DOI: 10.1016/j. diabet.2020.10.006
38. Fox T, Ruddiman, K, Lo KB, Peterson E, DeJoy R, Salacup G. The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis. Acta Diabetol. 2020 Aug 17 : 1–6. DOI: 10.1007/s00592-020-01592-8
39. Lampasona V, Secchi M, Scavini M, Bazzigaluppi E, Brigatti C, Marzinotto I. Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study. Diabetologia. 2020 Oct 8; 1-11. DOI: 10.1007/s00125- 020-05284-4
40. Lei M, Lin K, Pi Y, Huang X, Fan L, Huang J. Clinical Features and Risk Factors of ICU Admission for COVID-19 Patients with Diabetes. J Diabetes Res. 2020 Dec 11; 2020:5237840; DOI: 10.1155/2020/5237840
41. Sourij H, Aziz, F, Bräuer A, Ciardi C, Clodi M, Fasching P. COVID-19 fatality prediction in people with diabetes and prediabetes using a simple score upon hospital admission. Diabetes Obes Metab. 2021 Feb;23 (2):589-598. Epub 2020 Dec 4. DOI: 10.1111/dom.14256
42. Myers AK, Kim TS, Zhu X, Liu Y, Qiu, M, Pekmezaris R. Predictors of mortality in a multiracial urban cohort of persons with type 2 diabetes and novel coronavirus 19. J Diabetes. 2021 Feb 26; DOI: 10.1111/1753-0407.13158
43. Zhu Z, Mao Y, Chen G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. Prim Care Diabetes. 2021 Aug 11; S1751- 9918(21)00130-3. DOI: 10.1016/j.pcd.2021.07.013
44. Prattichizzo F, de Candia P, Nicolucci A, Ceriello A. Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis. Diabetes Metab Res Rev. 2021 May 20 e3476. DOI: 10.1002/dmrr.3476
45. Liu Z, Bai X, Han X, Jiang W, Qiu L, Chen S et al. The association of diabetes and the prognosis of COVID-19 patients: A retrospective study. Diabetes Res Clin Pract. 2020 Nov; 169:108386. Epub 2020 Aug 25. DOI: 10.1016/j. diabres.2020.108386
46. Cheng, Y, Yue L, Wang, Z, Zhang, J, Xiang G. Hyperglycemia associated with lymphopenia and disease severity of COVID-19 in type 2 diabetes mellitus. J Diabetes Complications. 2021 Feb; 35(2):107809. Epub 2020 Nov 26.DOI: 10.1016/j. jdiacomp.2020.107809
47. Lazarus G, Audrey J, Wangsaputra VK, Tamara A, Tahapary DL. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and doseresponse meta-analysis. Diabetes Res Clin Pract. 2021 Jan; 171: 108561.Epub 2020 Dec 9. DOI: 10.1016/j.diabres.2020.108561
48. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. Diabetes Care. 2020 July; 43(7): 1399-1407. DOI: 10.2337/dc20- 0660
49. Hui Y, Li Y, Tong X, Wang Z, Mao X, Huang L et al. The risk factors for mortality of diabetic patients with severe COVID-19: A retrospective study of 167 severe COVID-19 cases in Wuhan. PLoS One. 2020 Dec 31; 15(12): e0243602. DOI: 10.1371/ journal.pone.0243602
50. Li Y, Han X, Alwalid O, Cui Y, Cao Y, Liu J et al. Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Res Clin Pract. 2020 Aug; 166: 108299. Epub 2020 Jul 3. DOI: 10.1016/j.diabres.2020.108299
51. Mirani M, Favacchio G, Carrone F, Betella N, Biamonte E, Morenghi G. Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy. Diabetes Care. 2020 Dec; 43(12):3042-3049. DOI: 10.2337/dc20-1340
52. Zhang N, Wang C, Zhu F, Mao H, Bai P, Chen LL et al. Risk Factors for Poor Outcomes of Diabetes Patients With COVID-19: A Single-Center, Retrospective Study in Early Outbreak in China. Front Endocrinol (Lausanne). 2020; 11: 571037. Epub 2020 Sep 24; DOI: 10.3389/fendo.2020.571037
53. Chung SM, Lee, YY, Ha EY, Yoon JS, Won KC, Lee HW et al. The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study. Diabetes Metab J. 2020 Jun; 44(3): 405–413. Epub 2020 May 21; DOI: 10.4093/dmj.2020.0105
54. Khalil S, Sabaghian T, Sedaghat M, Soroureddin Z, Askari E, Khalili N. Prevalence, Risk Factors and Outcomes Associated with Acute Kidney Injury in Patients Hospitalized for COVID-19: A Comparative Study between Diabetic and Nondiabetic Patients. J Diabetes Res. 2021 Jan 6; 2021:6666086; DOI: 10.1155/2021/6666086
55. Rubino F, Amiel SA, Zimmet P, et al. New-Onset Diabetes in Covid-19. N Engl J Med. 2020 Aug 20;383(8):789-790. doi: 10.1056/NEJMc2018688. Epub 2020 Jun 12. PMID: 32530585; PMCID: PMC7304415.
56. Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020 Jun;164:108166. doi: 10.1016/j.diabres.2020.108166. Epub 2020 Apr 24.
57. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020. April 20 (Epub ahead of print).
58. Ren H, Yang Y, Wang F, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc Diabetol 2020;19:58-58. [PMC free article] [PubMed] [Google Scholar]
59. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020 May-Jun;14(3):211-212. doi: 10.1016/j.dsx.2020.03.002. Epub 2020 Mar 10. PMID: 32172175; PMCID: PMC7102582.
60. ARNO Diabetes Observatory. The care profile of the population with diabetes. Report 2019 Vol XXXI. www.arno.cineca.it, last consultation 28 May 2022